8-K: Zai Lab Narrows Q2 Loss, VYVGART Sales Surge 46%

Zai Lab Limited reported a significant reduction in its second-quarter 2025 operating loss and strong revenue growth, driven by record VYVGART utilization, while reaffirming full-year guidance.

Summary

• Total revenues for the second quarter of 2025 grew 9% year-over-year to $110.0 million.
• Product revenue, net, was $109.1 million in Q2 2025, a 9% year-over-year increase (10% at constant exchange rate).
• Operating loss improved by 28% year-over-year to $54.9 million for Q2 2025, and by 37% to $34.2 million on an adjusted basis.
• Net loss decreased to $40.7 million in Q2 2025, compared to $80.3 million for the same period in 2024.
• VYVGART and VYVGART Hytrulo sales reached $26.5 million in Q2 2025, a 46% quarter-over-quarter increase from $18.1 million in Q1 2025.
• ZEJULA sales were $41.0 million in Q2 2025, down from $45.0 million in Q2 2024 due to competitive dynamics.
• XACDURO, launched in Q4 2024, generated $4.6 million in Q2 2025.
• NUZYRA sales grew to $14.3 million in Q2 2025 from $12.3 million in Q2 2024.
• Research and Development (R&D) expenses decreased to $50.6 million in Q2 2025 from $61.6 million in Q2 2024.
• Selling, General and Administrative (SG&A) expenses decreased to $71.0 million in Q2 2025 from $79.7 million in Q2 2024.
• Cash and cash equivalents, short-term investments, and current restricted cash totaled $832.3 million as of June 30, 2025.

Sentiment

Score: 8

Explanation: The filing indicates strong positive momentum with significant improvements in financial performance (reduced losses), robust growth in key commercial products like VYVGART, and promising advancements across a diverse pipeline. The reaffirmation of full-year guidance and the path to profitability in Q4 2025 contribute to a highly positive outlook, despite some competitive pressures on ZEJULA.

Positives

• Total revenues grew 9% year-over-year to $110.0 million in Q2 2025.
• Operating loss improved significantly by 28% year-over-year to $54.9 million (37% adjusted to $34.2 million).
• Net loss decreased substantially to $40.7 million in Q2 2025 from $80.3 million in Q2 2024.
• VYVGART and VYVGART Hytrulo sales surged 46% quarter-over-quarter to $26.5 million, driven by increased utilization and longer treatment durations.
• VYVGART's role in myasthenia gravis (MG) treatment was strengthened by updated national guidelines in July 2025, recommending early and sustained use.
• ZL-1310 (DLL3 ADC) showed strong efficacy with a 67% Objective Response Rate (ORR) across all doses (79% at 1.6mg/kg) in second-line ES-SCLC, alongside a differentiated safety profile.
• ZL-1310 received U.S. FDA Fast Track designation in May 2025, accelerating its development.
• Bemarituzumab's Phase 3 FORTITUDE-101 study met its primary endpoint of overall survival in first-line gastric cancer, indicating strong potential.
• Tumor Treating Fields (TTFields) demonstrated an overall survival benefit and improved quality of life in the Phase 3 PANOVA-3 trial for pancreatic cancer.
• ZL-1503 (IL-13/IL-31R) preclinical data highlighted promising potential for moderate-to-severe atopic dermatitis with a favorable safety profile and durable suppression.
• The company is on track to achieve profitability (adjusted income from operations) in the fourth quarter of 2025.
• Reduced R&D and SG&A expenses reflect successful resource prioritization and efficiency efforts.

Negatives

• ZEJULA sales were softer, decreasing to $41.0 million in Q2 2025 from $45.0 million in Q2 2024, attributed to evolving competitive dynamics within the PARPi class.
• The company continues to report an operating loss of $54.9 million and a net loss of $40.7 million for the quarter.
• Cash position slightly decreased to $832.3 million as of June 30, 2025, from $857.3 million as of March 31, 2025.

Risks

• Ability to successfully commercialize and generate revenue from approved products.
• Ability to obtain funding for operations and business initiatives.
• Uncertainty regarding the results of clinical and pre-clinical development of product candidates.
• The content and timing of decisions made by relevant regulatory authorities regarding product candidate approvals.
• Risks associated with doing business in China.

Future Outlook

The company reaffirmed its full-year 2025 revenue guidance of $560 million to $590 million and remains on track to achieve profitability (adjusted income from operations) in the fourth quarter of 2025. Multiple high-impact launches, including KarXT and bemarituzumab, are anticipated to fuel future growth. The global pipeline is advancing with registrational studies planned for ZL-1310 in second-line ES-SCLC and VRDN-003 in thyroid eye disease in the second half of 2025, and a global Phase 1 study for ZL-1503 in moderate-to-severe atopic dermatitis. Regulatory submissions in China are expected for bemarituzumab, Tumor Treating Fields, and efgartigimod (prefilled syringe) in the second half of 2025.

Management Comments

• "We are making meaningful progress throughout our business – expanding patient impact, accelerating global innovation, and operating with financial discipline." Dr. Samantha Du, Founder, Chairperson, and CEO.
• "Updated ASCO data for ZL-1310 (DLL3 ADC) reaffirm its best-in-class potential in second-line SCLC, and we are moving swiftly into pivotal development while exploring opportunities in first-line SCLC and other neuroendocrine carcinomas." Dr. Samantha Du.
• "With multiple launches ahead, a robust pipeline, and profitability within reach, Zai Lab is executing on its vision to become a leading global biopharma company." Dr. Samantha Du.
• "VYVGART continues to lead our commercial momentum, with record patient utilization driven by longer treatment durations and growing adoption in the maintenance setting." Josh Smiley, President and COO.
• "The July update to national MG guidelines further strengthens VYVGART’s role in both acute and chronic care, and we expect momentum to accelerate in the second half." Josh Smiley.
• "With a 28% year-over-year reduction in operating loss and a 37% improvement on an adjusted basis, we are on track to achieve profitability in the fourth quarter." Josh Smiley.
• "Backed by a strong cash position, a growing commercial business, and an advancing global pipeline, Zai Lab is well equipped to deliver long-term shareholder value." Josh Smiley.

Industry Context

The announcement highlights Zai Lab's continued growth in the biopharmaceutical sector, particularly in oncology and immunology. The softer sales for ZEJULA reflect evolving competitive dynamics within the PARP inhibitor class, indicating increased market competition. Conversely, the strong performance of VYVGART, supported by updated national guidelines, demonstrates its growing market penetration and importance in the myasthenia gravis treatment landscape. The advancement of pipeline assets like ZL-1310 (DLL3 ADC) and bemarituzumab (FGFR2b) aligns with the industry trend of developing targeted therapies and antibody-drug conjugates for difficult-to-treat cancers. The preclinical data for ZL-1503 in atopic dermatitis also positions the company within the competitive and growing immunology market for inflammatory skin conditions.

Comparison to Industry Standards

• The filing does not provide specific comparable company financial data or detailed project-level comparisons to industry benchmarks.
• For ZEJULA, the filing notes 'evolving competitive dynamics within the PARPi class,' indicating that its performance is influenced by the broader competitive landscape for PARP inhibitors, without naming specific competitors or their results.
• ZL-1310 is highlighted for its 'best-in-class potential' in second-line SCLC, with an Objective Response Rate (ORR) of 67% across all doses (79% at 1.6mg/kg), and a 'differentiated safety profile' (6% Grade 3 TRAEs, no Grade 2 ILD, no drug discontinuations). This suggests a favorable profile compared to existing or developing treatments for ES-SCLC, which often have significant toxicity.
• Bemarituzumab's Phase 3 FORTITUDE-101 study met its primary endpoint of overall survival in first-line gastric cancer patients with FGFR2b overexpression, demonstrating its potential in a high unmet need area, though specific comparative efficacy data against other first-line gastric cancer treatments are not detailed in this filing.
• VYVGART's record patient utilization and 46% quarter-over-quarter sales growth indicate strong market adoption and competitive positioning within the gMG treatment space, further bolstered by its inclusion in updated national guidelines.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value due to improved financial performance, strong pipeline progress, and a clear path to profitability.
• Patients: Expanded access to innovative treatments through successful commercialization of approved products like VYVGART and anticipated launches of new therapies like KarXT and bemarituzumab. Pipeline advancements offer hope for new treatment options in areas of high unmet medical need.
• Employees: Continued focus on resource prioritization and efficiency efforts may impact personnel costs, but overall growth and pipeline expansion could lead to new opportunities.
• Customers (Healthcare Providers): Availability of new and improved treatment options, supported by clinical data and guideline recommendations, enhancing their ability to treat patients effectively.
• Suppliers/Partners: Ongoing collaborations and new partnerships (e.g., with Vertex for povetacicept) indicate continued business for suppliers and opportunities for partners.

Next Steps

• Initiate a global registrational study of ZL-1310 monotherapy in second-line ES-SCLC in the second half of 2025.
• Provide data update for ZL-1310 in second-line ES-SCLC in the second half of 2025.
• Provide data readout for dose escalation of ZL-1310 doublet in combination with atezolizumab in first-line ES-SCLC.
• Provide data readout from the global Phase 1/2 study of ZL-1310 in patients with selected solid tumors (other neuroendocrine carcinomas).
• Advance ZL-1503 into a global Phase 1 study in moderate-to-severe atopic dermatitis in the second half of 2025.
• Advance ZL-6201 into global Phase 1 development for patients with sarcoma and potentially other LRRC15-positive solid tumors.
• Move rapidly toward regulatory submission in China for bemarituzumab in first-line gastric cancer in the second half of 2025.
• File for regulatory approval in China for Tumor Treating Fields (TTFields) in first-line pancreatic cancer in the second half of 2025.
• Submit NMPA applications for efgartigimod (FcRn) for prefilled syringe in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) in the second half of 2025.
• Zai Lab partner Bristol Myers Squibb to provide data readout from the Phase 3 ADEPT-2 study of KarXT in Alzheimer's Disease Psychosis in the second half of 2025.
• Zai Lab and partner argenx to provide topline results from the Phase 2 study of efgartigimod in Lupus Nephritis (LN) in the fourth quarter of 2025.
• Zai Lab partner argenx to provide topline results from the global Phase 3 ADAPT-SERON study of efgartigimod in seronegative gMG in the second half of 2025.
• Zai Lab to join the registrational UNITY study of efgartigimod subcutaneous in Sjogren's disease in Greater China in the third quarter of 2025.
• Zai Lab plans to partner with Vertex to execute the global pivotal Phase 2/3 study of povetacicept in Primary Membranous Nephropathy (pMN) in Greater China, expected to start in the second half of 2025.
• Zai Lab to initiate a registrational study of VRDN-003 in thyroid eye disease in Greater China in the second half of 2025.
• Zai Lab partner argenx to provide topline results from the global Phase 3 ADAPT-OCULUS study of efgartigimod in ocular myasthenia gravis in the first half of 2026.
• Zai Lab partner Vertex will conduct an interim analysis of the global Phase 3 RAINIER study for IgA Nephropathy (IgAN) in the first half of 2026, with potential for U.S. accelerated approval.
• Zai Lab partner Viridian to provide topline results from the global registrational REVEAL-1 and REVEAL-2 studies of VRDN-003 in the first half of 2026.

Key Dates

Recommendation

Zai Lab's Q2 2025 results demonstrate significant operational improvements, with a substantial reduction in operating and net losses, driven by strong revenue growth from key products like VYVGART. The reaffirmation of full-year revenue guidance and the clear path to adjusted profitability by Q4 2025 signal strong financial discipline and execution. The robust pipeline, with multiple assets showing promising clinical data (ZL-1310, bemarituzumab) and nearing regulatory submissions or pivotal studies, provides substantial future growth catalysts. Despite some competitive pressures on ZEJULA, the overall trajectory is highly positive, suggesting a compelling investment opportunity for long-term growth.

Keywords

Biopharmaceutical, Oncology, Immunology, Neuroscience, Infectious Disease, SEC Filing, Financial Results, Drug Development, Clinical Trials, ZLAB, VYVGART, ZEJULA, ZL-1310, Bemarituzumab, Small Cell Lung Cancer, Gastric Cancer, Myasthenia Gravis, Atopic Dermatitis, Profitability